tbuckley/cabot-search huggingface dataset:
Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene <i>MSH6</i>
Authors: Amie M. Blanco, Scott Topper, Robert L. Nussbaum
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study
Authors: William Townsend, Christian Buske, Guillaume Cartron, David Cunningham, Martin JS Dyer, John G. Gribben, Georg Hess, Takayuki Ishikawa, Ulrich Keller, Michael Kneba, Ram Malladi, Jeffrey D Neidhart, Chiara Rusconi, Jun Zhu, Olivier Catalani, Andrea Knapp, Harald Zeuner, Michael Herold, Wolfgang Hiddemann, Robert Marcus
Journal: Blood (2018)
Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial
Authors: Fraser Brims, Samal Gunatilake, Iain Lawrie, Laura Marshall, Carole Fogg, Cathy Qi, Lorraine Creech, Nicola Holtom, Stephanie Killick, Bernard Yung, David Cooper, Louise Stadon, Peter Cook, Elizabeth Fuller, Julie Walther, Claire Plunkett, Andrew Bates, Carolyn Mackinlay, Anil Tandon, Nicholas A Maskell, Karen Forbes, Najib M Rahman, Stephen Gerry, Anoop J Chauhan
Journal: Thorax (2019)

Malignant pleural mesothelioma (MPM) has a high symptom burden and poor survival. Evidence from other cancer types suggests some benefit in health-related quality of life (HRQoL) with early specialist palliative care (SPC) integrated with oncological services, but the certainty of evidence is low.We performed a multicentre, randomised, parallel group controlled trial comparing early referral to SPC versus standard care across 19 hospital sites in the UK and one large site in Western Australia. Participants had newly diagnosed MPM; main carers were additionally recruited.review by SPC within 3 weeks of allocation and every 4 weeks throughout the study. HRQoL was assessed at baseline and every 4 weeks with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30.change in EORTC C30 Global Health Status 12 weeks after randomisation.Between April 2014 and October 2016, 174 participants were randomised. There was no significant between group difference in HRQoL score at 12 weeks (mean difference 1.8 (95% CI -4.9 to 8.5; p=0.59)). HRQoL did not differ at 24 weeks (mean difference -2.0 (95% CI -8.6 to 4.6; p=0.54)). There was no difference in depression/anxiety scores at 12 weeks or 24 weeks. In carers, there was no difference in HRQoL or mood at 12 weeks or 24 weeks, although there was a consistent preference for care, favouring the intervention arm.There is no role for routine referral to SPC soon after diagnosis of MPM for patients who are cared for in centres with good access to SPC when required.ISRCTN18955704.
Natural History of Functional Tricuspid Regurgitation
Authors: Philipp E. Bartko, Henrike Arfsten, Maria K. Frey, Gregor Heitzinger, Noemi Pavo, Anna Cho, Stephanie Neuhold, Timothy C. Tan, Guido Strunk, Christian Hengstenberg, Martin Hülsmann, Georg Goliasch
Journal: JACC. Cardiovascular imaging (2019)
Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting
Authors: Shaji K. Kumar, Alan Fu, Khalid Mezzi, Megan Braunlin, Christopher Kim, Karim Iskander, Ruben Niesvizky, Sundar Jagannath, Ralph Boccia, Noopur Raje
Journal: Blood (2018)
Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy
Authors: Pia Gamradt, Léo Laoubi, Audrey Nosbaum, Virginie Mutez, Vanina Lenief, Sophie Grande, Daniel Redoulès, Anne-Marie Schmitt, Jean-François Nicolas, Marc Vocanson
Journal: Journal of Allergy and Clinical Immunology (2019)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Authors: Edward A. Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven Devine, Yvonne Efebera, Siddharta Ganguly, Cristina Gasparetto, Nancy Geller, Mary M. Horowitz, John Koreth, Kristin Knust, Heather Landau, Claudio Brunstein, Philip McCarthy, Courtney Nelson, Muzaffar H. Qazilbash, Nina Shah, David H. Vesole, Ravi Vij, Dan T. Vogl, Sergio Giralt, George Somlo, Amrita Krishnan
Journal: Journal of Clinical Oncology (2019)

Single-cycle melphalan 200 mg/m
Drivers of Clinical Trial Participation—Demographics, Disparities, and Eligibility Criteria
Authors: Grace Mishkin, Fernanda Arnaldez, S. Percy Ivy
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A topological view of human CD34+ cell state trajectories from integrated single-cell output and proteomic data
Authors: David J. H. F. Knapp, Colin A. Hammond, Fangwu Wang, Nima Aghaeepour, Paul H. Miller, Philip A. Beer, Davide Pellacani, Michael VanInsberghe, Carl Hansen, Sean C. Bendall, Garry P. Nolan, Connie J. Eaves
Journal: Blood (2019)
After PCI with 2nd-generation DESs for STEMI, dual-antiplatelet therapy for 6 mo was noninferior to 12 mo
Authors: Stefanie Furlan, Steven Borzak
Journal: Annals of Internal Medicine (2019)

Source Citation Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018;363:k3793. 30279197
AB0246 Genetic variability with toll-like receptor 10 affects susceptibility to rheumatoid arthritis and modulates response to biological treatment
Authors: B. Wysoczanska, J. Swierkot, M. Puchala, K. Kolossa, S. Jeka, P. Wiland, K. Bogunia-Kubik
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Genetic variability in Toll-like receptor 10 (TLR10) may change the balance between pro- and anti-inflammatory responses, and hence modulate the susceptibility to infection and to autoimmune disease including rheumatoid arthritis (RA). <h3>Objectives</h3> Therefore we aimed to assess the possible associations of the TLR10 genetic variants with RA susceptibility and/or response to treatment <h3>Methods</h3> <i>TLR10</i> gene (rs 11096957, N241H, A&gt;C) polymorphism was genotyped by LightSNiP assay in 303 RA patients (237F/66M) and in 140 healthy individuals from Polish population. <h3>Results</h3> RA patients with the AC genotype showed predisposition to disease development [OR 1.99 (1.32–3.01); p=0.001], while the AA homozygosity seemed to play a protective role [OR 0.63 (0.42–0.95); p=0.034]. Response to treatment with TNF-alpha inhibitors was more effective after 6 months as compared to 3 months (p=0.001), especially in female patients (p=0.05). Women carrying the A allele responded better to treatment after 6 months of anti-TNF treatment as compared to those with the CC genotype (p=0.053). Response to biological treatment was more effective in patients with low stage of disease (p=0,01), with rheumatoid factor (RF) positivity (p=0.01) and with double positivity against cytrulinated (CCP) protein and RF (p=0.003). RF-positive patients (especially women, p=0.001) characterised with a higher degree of the disease as compared to RF-negative cases (p=0.01). Men had a higher activity of the disease before anti-TNF treatment (p=0.05), therefore the remission of the disease was more common in women (p=0.04). <h3>Conclusions</h3> These results imply that the TLR10 polymorphism has an important role in RA and may potentially influence risk of the disease and effectiveness of biological treatment. <h3>Acknowledgements</h3> Supported by the <sup>National Science Centre grant No. 2016/</sup>21/B/NZ5/01901. <h3>Disclosure of Interest</h3> None declared
Abstract 17093: Variation in Survival After Out-of-Hospital Cardiac Arrest Among Prefectures in Japan
Authors: Masashi Okubo, Koichiro Gibo, Junichi Izawa, Kosuke Kiyohara, Sho Komukai, David Wallace, Clifton Callaway, Taku Iwami, Tetsuhisa Kitamura
Journal: Circulation (2017)

Introduction: Reasons for the marked regional variation in survival after out-of-hospital cardiac arrest (OHCA) are poorly understood. We evaluated the variability in OHCA outcome among 47 prefectures in Japan. Hypothesis: Patient- and prefecture-level variables partially explain the variation in OHCA outcome among prefectures. Methods: Using the nationwide population-based OHCA registry in Japan, we evaluated 1-month survival with favorable neurological outcome, defined Cerebral Performance Category 1 or 2 after EMS-treated OHCA of medical origin during 2014. We used hierarchical regression models with patients nested within prefecture adjusting for patient-level variables (age, sex, initial rhythm, etiology of arrest, witness status, bystander CPR, public AED shock delivery, pre-hospital epinephrine administration, pre-hospital advanced airway management, EMS defibrillation, EMS call-to-EMS CPR time, and EMS call-to-hospital arrival), and prefecture-level variables (number of CPR trainees, AED, and EMS ...
FRI0096 Is side effects and treatment response to methotrexate associated to comorbidity in early rheumatoid arthritis
Authors: K.L. Pedersen, J. Hallas, I.M.J. Hansen, P. Ahlquist, T. Ellingsen
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> In Denmark approximately 0.7% (35.000) of the population is diagnosed with rheumatoid arthritis (RA). RA is a risk factor in development of comorbidity, and comorbidities are not well managed in RA patients. In addition of being first line treatment of early RA, methotrexate (MTX) gives a 70% reduction in cardiovascular disease caused mortalities, and if treatment exceeds a year, the general mortality risks are lowered by 60%. Discontinuation of MTX is therefore a bad outcome for RA. It remains unclear whether side effects and treatment response to MTX is associated to comorbidity in early RA. <h3>Objectives:</h3> To evaluate the association between comorbidity and persistence to MTX treatment and side effects for RA patients. <h3>Methods</h3> Patient files from three centres were evaluated retrospectively. Inclusion criteria were: diagnosis obtained according to ACR/<sup>EULAR 2010</sup> criteria for RA in the period 01/01/2010 to present, and MTX as first line of treatment. Medical records were reviewed for side effects, dose changes of MTX, formulation changes and persistence. Comorbidities and comedication was evaluated by usage of the Danish National Patient Registry (DNPR), and the Odense Pharmacoepidemiological Database (OPED). Comorbidities were scored according to the Charlson Comorbidity Index (CCI), and analysed by the cox proportional hazards model for discontinuation of MTX treatment and dose reduction. <h3>Results:</h3> 501 patients were screened, 177 were eligible and analysed at baseline for disease characteristics, medication besides MTX and comorbidities in a 5 year window before RA diagnosis baseline. The highest risk of MTX discontinuation was a CCI of 3–4, they had crude 4.18 (95% CI 1.67–10.45) increased risk compared to the reference group (RA with no comorbidities). Risk of dosage reduction was highest at CCI 1–2: 1.38 (95% CI 0.72–2.62). A CCI of 5 or higher gave a −4.83 mg (95% CI −10.24- −0.59) adjusted difference in maximum weekly tolerable MTX dosage. Side effects occurred for 23.7%. Most likely dosage causing side effect was 20 mg (IQR 15–20 mg). Nausea occurred in 29% and hepatic events 21%. <h3>Conclusions:</h3> Patients with CCI in the range of 3–4 had an increased risk for discontinuing MTX treatment. <h3>Disclosure of Interest</h3> None declared
Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Authors: Eric A. Secemsky, Enrico G. Ferro, Sunil V. Rao, Ajay Kirtane, Hector Tamez, Pearl Zakroysky, Daniel Wojdyla, Steven M. Bradley, David J. Cohen, Robert W. Yeh
Journal: JAMA Cardiology (2019)

Following negative randomized clinical trials, US guidelines downgraded support for routine manual aspiration thrombectomy (AT) during primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI). However, some PCI operators continue to endorse a clinical benefit with AT use despite the lack of supportive data.To examine temporal trends and comparative outcomes of AT use during pPCI for STEMI.Retrospective cohort study of the National Cardiovascular Data Registry (NCDR) CathPCI Registry from July 1, 2009, to June 30, 2016, to assess temporal trends and in-hospital outcomes associated with AT use. To evaluate outcomes through 180 days, a subanalysis was conducted among Centers for Medicare and Medicaid Services-linked patients from July 1, 2009, through December 31, 2014. The comparative effectiveness analysis was performed using instrumental variable analyses to account for treatment selection bias. The instrumental variable was operator's preference to use AT during pPCI. Data were analyzed between February 1, 2017, and April 1, 2018.Aspiration thrombectomy use during pPCI for STEMI.Primary outcomes included in-hospital stroke and death. Secondary outcomes included heart failure, stroke, all-cause rehospitalization, and death through 180 days of follow-up.Among all pPCIs performed (683 584), the mean (SD) age of patients was 61.7 (12.8) years, 489 257 were male (71.6%), and 596 384 were white (87.2%). Among patients undergoing pPCI, AT use increased from 2009 through 2011, with peak use of 13.8%. This was followed by a decline of more than 9%, reaching 4.7% by mid-2016. Overall, AT was used in 10.8% of pPCIs (lowest operator group median, 0%; highest operator group median, 33.8%). After instrumental variable analysis, AT use was associated with no difference in in-hospital death (adjusted absolute risk difference, -0.18%; 95% CI, -0.53% to 0.16%; P = .29) and a small increase in in-hospital stroke (adjusted RD, 0.14%; 95% CI, 0.01%-0.30%; P = .03). Among Centers for Medicare and Medicaid Services-linked patients, AT use was not associated with differences in death, heart failure, stroke, or rehospitalization at 180 days.In this large, nationwide analysis, AT use during STEMI pPCI declined by more than 50% since 2011, with use as of mid-2016 at less than 5%. Selective AT use was associated with a small excess risk of in-hospital stroke and no difference in other outcomes through 180 days of follow-up.
Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial
Authors: Davine Hofste op Bruinink, Mark van Duin, Meral Beksac, Christoph Driessen, Heinz Ludwig, Michael Vermeulen, Rowan Kuiper, Martin H van Vliet, Bronno van der Holt, Roman Hajek, Hans Erik Johnsen, Meletios A Dimopoulos, Antonio Palumbo, Michele Cavo, Pieter Sonneveld
Journal: Blood (2018)
OP0346-PARE A partnership in implementation: adapting an osteoarthritis guidebook across european cultures – with patients, for patients
Authors: L. Campbell, JIGSAW-E Patient Champions, S. Blackburn, J. Meesters, M. De Wit, D. Schiphof, T. Vliet Vlieland, S. Bierma-Zeinstra, N. Østerås, S. Pais, E. Roos, N. Evans, K. Dziedzic
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> A guidebook for patients with osteoarthritis (OA) was co-developed with UK patients during an OA research study.<sup>1–3</sup> The JIGSAW-E project is now disseminating and implementing the OA management guidelines and Guidebook in clinical practice in UK, Netherlands, Norway, Denmark and Portugal.<sup>4</sup> <h3>Objectives</h3> To study the translation and cultural adaptations of the OA Guidebook appropriate for local context and use by patient champions and health professionals together. <h3>Methods</h3> A project launch meeting led to the creation of an international panel of Patient Champions and the adaptation of the OA Guidebook as a priority project. 15 Patient Champions with OA were collaborative partners of the project's local Communities of Practices (CoP) (UK:2, Norway:2, Netherlands:5, Denmark:5, Portugal:1) (figure 1). CoPs also engaged with OA patient organisations. Cultural adaptation of the OA Guidebook by CoPs: 1) review of UK OA Guidebook and existing written patient information; 2) translation; 3) cultural adaptation: review of content, images and layout; 4) consistency check with national guidelines; 5) production; 6) review and approval; 7) shared learning across countries via Skype. Each CoP adopted a process appropriate to their specific context <h3>Results</h3> <h3>Conclusions</h3> It is feasible and effective to involve patient champions in the cultural adaptation and dissemination of consistent and accurate patient information to support the implementation of OA guidelines in clinical practice. <h3>References</h3> [1] ] Health Expect2014;17:164–73. [2] ] BMC Musculoskelet Disord2014;15:427. [3] ] Osteoarthritis Cartilage2018;26:43–53. [4] ] Physiotherapy2016;102:e138–9. <h3>Acknowledgements</h3> Thank you to all the Patient Champions for their contributions to JIGSAW-E. A. Rosager and L. Baumbasch led the Danish adaptation. JIGSAW-E is funded by EIT Health. KD is part funded by a NIHR Knowledge Mobilisation Research Fellowship (KMRF201403002). The MOSAICS study was funded by NIHR Programme Grant (RP-PG-0407–10386). <h3>Disclosure of Interest</h3> None declared
THU0268 The frequency of juvenile spondyloarthropathies in childhood famillial mediterranean fever
Authors: E. Ozer, D. Seker, H.E. Taner, A. Adrovic, S. Sahin, O. Koker, K. Barut, O. Kasapcopur
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease characterised with fever, recurrent episodes of self-limiting polyserositis and arthritis. FMF arthritis is generally acute monoarthritis especially in the larger joints of the lower extremities, healing without a sequelae. However some of the patients develop different type of chronic arthritis, predominantly oligoarticular juvenile idiopathic arthritis (JIA) and juvenile pondyloarthropathies<b> (</b>JSpA). Studies on JSpA among childhood FMF patients are spare. <h3>Objectives</h3> To evaluate frequency of JSpA in a large childhood FMF cohort. Furthermore, we aimed to define main characteristics of JSpA among childhood FMF patients. <h3>Methods</h3> A total of 320 juvenile FMF patients were blindly questioned according to recently proposed criteria for JSpA by 3 researchers (EO, DS, ET) that were previously educated for FMF and JSpA. A standardised case report form was prepared and completed for each patient. This form was including demographic data, clinical features, MEFV mutation and treatment. Patients fulfilled the JSpA criteria and were classified as probable JSpA. Afterwards, an expert in paediatric rheumatology (OK) reevaluated the classified patients and some of them were confirmed to be a definite while some of them were accepted as potential JSpA patients. <h3>Results</h3> As a result, 37 patients (11.5%) were initially classified as potential JSpA. Furthermore, 32 (10%) of them were accepted as definite and 5 (1.5%) patients as probable JSpA in childhood FMF. Demographic, clinical and treatment data of definitive JSPA patients are shown in Table <b>I.</b> The most frequent MEFV mutation among JSPA patients was M694V (63.33%). <h3>Conclusions</h3> Articular involvement compatible with JSpA could be seen in childhood FMF patients. Spondyloarthropathy was detected in 10% of childhood FMF cases. The M694V mutation is the most common MEFV mutation among JSpA patients with FMF. JSpA should be considered in childhood FMF patients, especially in those chronic arthritis, axial involvement and enthesopathy. <h3>Reference</h3> [1] Adrovic A, Sezen M, Barut K, et al. The performance of classification criteria for juvenile spondyloarthropathies. Rheumatol Int2017;37:2013–2018. <h3>Disclosure of Interest</h3> None declared
Boric acid induces apoptosis in both prostate and breast cancer cell lines
Authors: Stephen Carper, Anu Elegbede, Casey Hall, Shirley Shen, Susan Meacham
Journal: Cancer Research (2007)

4220  Boron is an essential nutrient for higher plants but its role in  animals is unknown. Studies have reported that boron had  beneficial effects on embryogenesis in fish and rats and mineral  metabolism in chickens. In a typical adult human diet, daily  intakes of boron were reported to be approximately 1 - 2 mg/day.  The major form of boron in humans is boric acid, a weak acid (pKa  =9.2), mostly unionized at physiological pH. Recent reports have  indicated that boric acid is able to inhibit the growth of prostate  cancer cell lines and tumors. Our studies confirm growth  inhibition of the DU-145 and PC-3 human prostate cancer cells  >lines. In addition, we have observed that boric acid is also capable  >of inhibiting the growth of two human breast cancer cell lines ZR-  >75-1 and SK-BR-3 but not MDA-MB-231, MDA-MB-435, T-47D  >or MCF-7 breast cancer cell lines. In addition to growth inhibition  >it was observed that boric acid and phenyl boric acid were able to  >cause both the breast and prostate cancer cells to detach and  >undergo apoptosis. Flow cytometery indicated that the floating  >cells were undergoing apoptosis in a dose dependent manner. A  >caspase 3 assay further confirmed apoptosis. Both boric acid and  >phenyl boric acid were able to inhibit the attachment of DU-145 in  >the absence or presence of MnCl2. Cell attachment is controlled  >by the integrin proteins hence, our working hypothesis is that boric  >and phenyl boric acids are binding to the integrin proteins, causing  >the cells to detach and undergo apoptosis.